

CLAIMS:

- 1 1. A stable pharmaceutical composition for oral administration of ACE inhibitor(s)
2 comprising a core coated with a layer of ACE inhibitor(s).
- 1 2. The composition of claim 1, wherein the said layer is without plasticizer.
- 1 3. The composition of claim 1, wherein the ACE inhibitor is selected from the group
2 consisting of ramipril, quinapril, enalapril, spirapril, lisinopril, and benazepril.
- 1 4. The composition of claim 1, wherein the layer of ACE inhibitor(s) comprises film
2 forming polymer.
- 1 5. The composition of claim 4, wherein the film forming polymer is selected from the
2 group consisting of hydroxypropylcellulose, hydroxypropylmethylcellulose,
3 hydroxyethylcellulose, ethylcellulose, cellulose acetate, polyvinylpyrrolidone, gelatin,
4 a combination of microcrystalline cellulose and carrageenan, and a combination of
5 polyvinylalcohol and polyvinylacetate.
- 1 6. The composition of claim 4, wherein the layer of ACE inhibitor(s) further comprises
2 other additives.
- 1 7. The composition of claim 1, wherein the core is a compressed tablet.
- 1 8. The composition of claim 1, wherein the core comprises a sugar sphere or nonpareil
2 seeds.
- 1 9. The composition of claim 7 or 8, wherein compressed tablets, sugar spheres or
2 nonpareil seeds are filled into hard gelatin capsules.
- 1 10. The composition of claim 1, wherein the core is inert.
- 2 11. The composition of claim 1, wherein the core has a pharmaceutically active substance
3 other than the one which is susceptible to degradation by mechanical stress.
- 1 12. The composition of claim 11 wherein the pharmaceutically active substance is selected
2 from the group consisting of hydrochlorothiazide, piretanide, and dihydropyridines

- 1 13. The composition of claim 12, wherein the dihydropyridines are selected from the
2 group consisting of felodipine, nitrendipine, nifedipine and lacidipine.
- 1 14. A stable pharmaceutical composition for oral administration of pharmaceutically
2 active substance, comprising a core coated with a layer of pharmaceutically active
3 substance, wherein the pharmaceutically active substance is susceptible to degradation
4 by mechanical stress.
- 5 15. The composition of claim 1, wherein a seal coat separates the core and the layer of
6 ACE inhibitor(s).
- 1 16. The composition of claim 1, wherein the layer of ACE inhibitor(s) is further
2 surrounded with an outer coat.
- 1 17. A process for the preparation of a stable pharmaceutical composition for oral
2 administration of ACE inhibitor(s) comprising disposing a layer of an ACE inhibitor
3 dispersion, suspension or solution onto a core.
- 1 18. The process of claim 17, wherein the layer is disposed as a coating dispersion.
- 1 19. The process of claim 18, wherein the coating dispersion is made in aqueous solvent.
- 1 20. The process of claim 17, wherein the dispersion is sprayed on the cores.
- 1 21. A method of treating a disorder selected from the group consisting of hypertension,
2 congestive heart failure left ventricular dysfunction and diabetic nephropathy, the
3 method comprising administration of a therapeutically effective amount of the
4 pharmaceutical composition of claim 1 to a patient suffering from such disorder.